Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...
Vancouver, BC, January 15, 2025--(T-Net)--AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell ...
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare Conference in San Francisco. The two ...
AbbVie bought the rights to SIM0500, a trispecific T-cell engager for multiple myeloma, from Chinese pharmaceutical company Simcere Zaiming for an undisclosed upfront payment and up to $1.05 billion ...
AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion ...
AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion ...
T-cell engagers have been hot property in recent months, so it’s only right that one the biggest deals to kick off the J.P. Morgan Healthcare conference should see AbbVie expanding its interest ...
Inquiries Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774 Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005 Investor Relations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback